XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 173 Months Ended
Nov. 30, 2009
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Dec. 31, 2023
License Agreements          
Total revenues   $ 880,889 $ 808,673    
JAKAFI          
License Agreements          
Total revenues   571,839 579,969    
Novartis | JAKAFI | UNITED STATES          
License Agreements          
Total revenues   23,000 23,400    
Royalties payable   398,600   $ 398,600 $ 375,600
Novartis | JAKAVI          
License Agreements          
Total revenues   89,600 76,700    
Novartis | TABRECTA          
License Agreements          
Total revenues   $ 5,200 $ 4,200    
Maximum | Novartis | JAKAVI          
License Agreements          
Royalty payments on future global net sales (as a percent)   14.00%      
Minimum | Novartis | JAKAVI          
License Agreements          
Royalty payments on future global net sales (as a percent)   12.00%      
Development Milestones | Novartis          
License Agreements          
Amount recognized and received for the achievement of a predefined milestone       157,000  
Development Milestones | Maximum | Novartis          
License Agreements          
Upfront and immediate milestone payment to be received under license agreement $ 174,000        
Regulatory Milestones | Novartis          
License Agreements          
Amount recognized and received for the achievement of a predefined milestone       345,000  
Regulatory Milestones | Maximum | Novartis          
License Agreements          
Upfront and immediate milestone payment to be received under license agreement 495,000        
Commercialization Milestones | Novartis          
License Agreements          
Amount recognized and received for the achievement of a predefined milestone       $ 200,000  
Commercialization Milestones | Maximum | Novartis          
License Agreements          
Upfront and immediate milestone payment to be received under license agreement 500,000        
Development and Regulatory Milestones | Maximum | Novartis | GVHD          
License Agreements          
Upfront and immediate milestone payment to be received under license agreement $ 75,000